MedDataX Logo

Prognosis Association of Hypocalcemia on Moderate-severe TBI, COHORTE STUDY

NCT ID: NCT01236911

Last Updated: 2010-11-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-10-31

Study Completion Date

2012-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Will have bad prognosis the patients with low calcium (less of 24 hrs of te admission in hospital)after moderate - severe TBI that the patients that do not developed this condition?

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Through the years the investigators have seen that the patients with low calcium after moderate-severe TBI had bad prognosis including more complications, and more days in hospital. The investigators want to make an association between the patients that developed this condition and the patients that do not developed this condition

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Calcium , Prognosis in Patients

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Calcium , TBI,complications, days in hospital

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Calcium after moderate-severe TBI

Patients with moderate -severe TBI with less as 24 hrs , admitted in emergency. We will measure seric calcium to compare the differences between both groups

Calcium Measurement

Intervention Type OTHER

after moderate-severe TBI (less as 24 hrs)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Calcium Measurement

after moderate-severe TBI (less as 24 hrs)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Man - woman between 16-65 years old with moderate -severe TBI less as 24 hrs,Count with tomographic study

Exclusion Criteria

* Use of steroids, use of statins, Administration of Tromethamine, calcium antagonists, fibrates, niacin, cyclosporine, macrolides.
* Unclassifiable lesions in brainstem
Minimum Eligible Age

16 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Universidad Autonoma de San Luis Potosí

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

UASLP fACULTY OF MEDICINE

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Juan Manuel Viñas Rios

San Luis Potosí City, San Luis Potosí, Mexico

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Mexico

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Juan manuel Viñas, M.D.

Role: CONTACT

Phone: 0052 44 48 262344

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Juan Manuel Viñas, M.D.

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NCT071110

Identifier Type: -

Identifier Source: org_study_id